A Trial of SHR-2173 in Healthy Volunteers

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Study completion date changed from estimate of Aug 30, 2026 to Sep 28, 2026
    • Interventions: SHR-2173 Injection/SHR-2173 placebo (Drug) to SHR-2173 Injection/SHR-2173 placebo (Drug)
    • Eligibility criteria expanded, about 12 words
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Primary completion moved earlier from Aug 30, 2026 to May 22, 2026
    • Site details revised
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 15, 2026 to Mar 6, 2026
    • Site details revised
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of SHR-2173 in healthy participants
Trial Details
NCT Number NCT07390747
Lead Sponsor Atridia Pty Ltd.
Conditions
(from sponsor)		 Immunology
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov